Clinical trials
Relapsed Large B-cell Lymphoma clinical trials
Below are recruiting relapsed large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 236 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06565689RecruitingPhase 1
YK012 for B-cell non-Hodgkin lymphoma after prior treatments
This study tests a new daily pill called YK012 for people with certain types of B-cell non-Hodgkin lymphoma that have not responded to at least two prior treatments. The goal is to see if it is safe and if it can shrink tumors.
Beijing, Beijing MunicipalityAges 18–65 - NCT06550141RecruitingPhase 2
Preventing side effects of CAR-T therapy for large B-cell lymphoma
This trial tests whether a drug called emapalumab can reduce serious side effects from CAR-T cell therapy, a treatment for large B-cell lymphoma that has come back or not responded to earlier treatments. If you qualify, you would receive emapalumab alongside your CAR-T treatment to help make it safer.
Boston, MassachusettsAges 18 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90 - NCT06542250RecruitingPhase 1/Phase 2
Study of a new immune therapy for relapsed B-cell cancers
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
La Jolla, CaliforniaAges 18 years+ - NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
Denver, ColoradoAges 18 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT06528301RecruitingPhase 1
Trial of UB-VV111 with or without rapamycin for B-cell cancers
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06526793RecruitingPhase 2
Surovatamig for relapsed or refractory B-cell lymphoma
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
Phoenix, ArizonaAges 18 years+ - NCT06508931RecruitingPhase 2
Zamtocabtagene autoleucel for children with B-cell lymphoma or leukemia
This trial tests a new CAR T-cell therapy (zamtocabtagene autoleucel) for children and teens whose B-cell lymphoma or leukemia has come back or hasn't responded to other treatments. The goal is to see if this one-time infusion can help their immune system fight the cancer.
Paris, Boulevard Sérurier 48Ages 6 months–17 years - NCT06484920RecruitingPhase 2
Pembrolizumab and ATRA for relapsed lymphoma
This trial tests a new combination of two medicines, pembrolizumab and ATRA (a form of vitamin A), for people with certain lymphomas that have come back or stopped responding to earlier treatments. The goal is to see if the combination can help the immune system fight the cancer more effectively.
Indianapolis, IndianaAges 18 years+ - NCT06486051RecruitingPhase 2
CAR T-cell therapy for adults with relapsed large B-cell lymphoma
This trial tests a new treatment called atlacabtagene autoleucel, which uses your own immune cells to fight the lymphoma. It's designed for people whose lymphoma has come back or not responded to initial treatments.
Auckland, AucklandAges 18–75 - NCT06458439RecruitingPhase 2
Epcoritamab with CAR T cells for large B-cell lymphoma
This trial tests a combination of two immune therapies—epcoritamab (a bispecific antibody) and CAR T cells—for people with large B-cell lymphoma whose cancer didn't respond to first treatment. The goal is to see if this combination works better than CAR T cells alone.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06120166RecruitingEarly Phase 1
Metabolically armed CAR-T cells for relapsed B-cell lymphoma
This trial tests a new type of CAR-T cell therapy (Meta10-19) for people with aggressive B-cell lymphoma that has not responded to two or more standard treatments. The therapy is designed to be more powerful inside the body to attack cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT06378190RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
Barcelona, BarcelonaAges 18–80 - NCT06365671RecruitingPhase 2
CAR-T therapy after stem cell transplant for high-risk B-cell lymphoma
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
ShanghaiAges 18 years+ - NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Sacramento, CaliforniaAges 18 years+ - NCT06340737RecruitingPhase 1
CD22-targeting CAR T cells for relapsed B cell lymphoma
This trial tests whether giving modified immune cells (CAR T cells) that target CD22 on cancer cells can help people with certain B-cell lymphomas that have come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors or control the disease.
Palo Alto, CaliforniaAges 18 years+ - NCT05794958RecruitingPhase 1
Safety of second CAR-T re-infusion for hard-to-treat lymphoma
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Palo Alto, CaliforniaAges 18 years+ - NCT06271057RecruitingPhase 2
Golcadomide after CAR T-cell for high-risk large B-cell lymphoma
This trial tests a new drug, golcadomide, given after CAR T-cell therapy to prevent relapse in people with aggressive large B-cell lymphoma who are at high risk. If you've had or are about to receive CAR T-cells, this study may help keep your lymphoma in remission.
CréteilAges 18 years+ - NCT06208735RecruitingPhase 1
CLIC-2201 for relapsed or refractory B cell cancers
This trial tests a new treatment called CLIC-2201 for people with certain types of B cell lymphoma or leukemia that have come back or not responded to previous treatments. It aims to see if this therapy can help control the cancer.
Calgary, AlbertaAges 1 year+ - NCT06189391RecruitingPhase 1
Testing CN201 for people with relapsed or refractory B-cell lymphoma
This study tests a new drug called CN201 (also known as MK-1045) for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06191887RecruitingPhase 1
BAFFR-targeting CAR-T cells for relapsed B-cell blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Jacksonville, FloridaAges 18 years+ - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
Los Angeles, CaliforniaAges birth–18 years - NCT06167785RecruitingPhase 2
Study of zanubrutinib and tislelizumab for lymphoma after CAR-T
This trial tests two new drugs (zanubrutinib and tislelizumab) for people with large B-cell lymphoma that has come back or not responded after CAR-T therapy. The goal is to see if these drugs can help when CAR-T hasn't worked.
Toronto, OntarioAges 18 years+
Hear when a new Relapsed Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed large b-cell lymphoma?
- Yes. Clin2 currently lists 236 recruiting relapsed large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Diffuse Large B Cell Lymphoma Relapsed
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Large B-cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.